SCHOTT Pharma : Financial Factsheet Q2 & H1 2026

About this update from Schott Pharma Ag & Co. Kgaa

‌SCHOTT Pharma Results of operations (in EUR m) Q2 2026 Q2 2025 ∆ in % Revenue 247.9 251.7 -1.5% Share of High-value solutions (HVS) 55% 55% - EBITDA 64.6 71.8 -10.1% EBITDA margin 26.0% 28.5% - EBIT 42.7 52.7 -19.0% EBIT margin 17.2% 20.9% - Financial result -2.4 -3.1 -23.5% Income tax expenses -9.2 -11.3 -18.8% Profit for the period 31.1 38.3 -18.7% Earnings per share (in EUR) 0.21 0.25 -16.0% Financial position (in EUR m) Q2 2026 Q2 2025 Cash flows from operating activities 91.7 47.5 Cash flows from ongoing investing activities -26.5 -29.3 Free cash flow 65.2 18.2 Net assets (in EUR m) Mar. 31, 2026 Sep. 30, 2025 Working capital 217.5 199.3 Working capital in % of revenue 21.9% 20.2% Equity ratio 58.6% 55.9% Net debt 110.0 122.2 Employees Mar. 31, 2026 Sep. 30, 2025 Revenue bridge (in EUR m) -0.0% -1.5% -1.5% 251.7 -0.1 247.9 -3.7 Q2 2025 Organic growth FX Q2 2026 Revenue by region (in EUR m) 22.7 65.7 43.7 119.6 Q2 2025 22.0 49.1 37.3 139.5 Q2 2026 ∆ in % +16.6% -14.6% -25.3% -3.1% EMEA APAC North America South America Headcount (as of the reporting date) 4,839 4,811 Drug Containment Solutions (DCS) Results of operations (in EUR m) Q2 2026 Q2 2025 ∆ in % Revenue 149.2 142.8 +4.5% EBITDA 38.4 33.2 +15.7% EBITDA margin 25.7% 23.2% - EBIT 28.2 23.8 +18.5% EBIT margin 18.9% 16.7% - Revenue bridge (in EUR m) +7.3% -2.8% +4.5% 149.2 142.8 +10.5 -4.1 Q2 2025 Organic growth FX Q2 2026 Drug Delivery Systems (DDS) Results of operations (in EUR m) Q2 2026 Q2 2025 ∆ in % Revenue 98.8 109.1 -9.5% EBITDA 26.9 37.4 -28.0% EBITDA margin 27.2% 34.2% - EBIT 15.4 27.9 -44.7% EBIT margin 15.6% 25.5% - Revenue bridge (in EUR m) -9.8% +0.3% -9.5% 109.1 +0.4 98.8 -10.7 1 Q2 2025 Organic growth FX Q2 2026 ‌SCHOTT Pharma Results of operations (in EUR m) H1 2026 H1 2025 ∆ in % Revenue 488.1 483.1 +1.0% Share of High-value solutions (HVS) 56% 55% - EBITDA 129.8 130.5 -0.6% EBITDA margin 26.6% 27.0% - EBIT 86.5 92.9 -6.9% EBIT margin 17.7% 19.2% - Financial result -4.1 -6.5 -36.1% Income tax expenses -17.9 -18.3 -2.2% Profit for the period 64.4 68.1 -5.4% Earnings per share (in EUR) 0.43 0.45 -4.4% Financial position (in EUR m) H1 2026 H1 2025 Cash flows from operating activities 95.1 72.6 Cash flows from ongoing investing activities -49.7 -50.3 Free cash flow 45.4 22.3 Net assets (in EUR m) Mar. 31, 2026 Sep. 30, 2025 Working capital 217.5 199.3 Working capital in % of revenue 21.9% 20.2% Equity ratio 58.6% 55.9% Net debt 110.0 122.2 Employees Mar. 31, 2026 Sep. 30, 2025 Revenue bridge (in EUR m) +2.3% -1.3% +1.0% 488.1 483.1 -6.1 +11.1 H1 2025 Organic growth FX H1 2026 Revenue by region (in EUR m) 43.2 109.5 87.6 242.8 H1 2025 44.2 92.3 75.1 276.5 H1 2026 ∆ in % +13.9% -14.3% -15.8% +2.4% EMEA APAC North America South America Headcount (as of the reporting date) 4,839 4,811 Drug Containment Solutions (DCS) Results of operations (in EUR m) H1 2026 H1 2025 ∆ in % Revenue 286.4 271.1 +5.7% EBITDA 71.8 61.3 +17.2% EBITDA margin 25.1% 22.6% - EBIT 52.3 42.9 +22.1% EBIT margin 18.3% 15.8% - Revenue bridge (in EUR m) +8.3% -2.7% +5.7% -7.2 286.4 271.1 +22.6 H1 2025 Organic growth FX H1 2026 Drug Delivery Systems (DDS) Results of operations (in EUR m) H1 2026 H1 2025 ∆ in % Revenue 201.8 212.2 -4.9% EBITDA 59.5 72.5 -18.0% EBITDA margin 29.5% 34.2% - EBIT 36.1 53.7 -32.9% EBIT margin 17.9% 25.3% - Revenue bridge (in EUR m) -5.4% +0.5% -4.9% 212.2 +1.1 201.8 -11.5 H1 2025 Organic growth FX H1 2026 1 1

View stock analysis, news, and events for Schott Pharma Ag & Co. Kgaa